Document:

Exhibit 10.2

 

EXTENSION TO EMPLOYMENT AGREEMENT

 

 

This Extension to Employment
Agreement (the “Extension”) effective as of July 1, 2022, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive,
Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT
06484 (“the Company,” and collectively with the Employee, the “Parties”).

 

WHEREAS, the Parties
entered into that certain Employment Agreement on July 11, 2018 which expired pursuant to its terms on June 30, 2021 which was subsequently
extended to June 30, 2022 (the “Employment Agreement”);

 

WHEREAS, the parties
hereto desire to extend the term of the Employment Agreement and to add to and/or revise the terms and conditions of the Employment Agreement;
and

 

WHEREAS, the Parties
hereto desire that all other terms and conditions of the Employment Agreement not specifically amended hereby will remain in full force
and effect;

 

NOW THEREFORE, in consideration
of the foregoing and the mutual agreements set forth herein, and for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

1. Term

 

The term of the Employment
Agreement shall be extended for an additional one (1) year term beyond the extended Term and that Section 2 of the Employment Agreement
is amended by replacing Section 2 as follows:

 

The term of this Agreement
shall commence on July 1, 2022 and shall continue for one (1) year, i.e. ending June 30, 2023, but subject to the approval of the Board
of Directors, renewable annually thereafter upon approval of the Board of Directors, provided that either party can terminate the employment
at any time, for any reason, upon 30 days’ notice (the “Employment Period”).

 

2.  Compensation and Benefits

 

Section 5 of the Employment
Agreement is amended by replacing Section 5 as follows:

 

The total compensation consists
of base salary, fringe benefits, stock awards, incentive awards, and performance bonuses as follows:

 

	 	A.	Base Salary and Fringe Benefits

 

As compensation for the Employee’s
services hereunder during the Employment Period, the Company shall pay the Employee a base salary of four hundred thousand ($400,000)
dollars per annum, commencing July 1, 2022, and through the effective period of the contract unless amended by the Compensation Committee.
Any base salary payable hereunder shall be paid in regular intervals in accordance with the Company’s payroll practices, but no
less frequently than once each month. The Employee shall be entitled to participate in all fringe benefits the Company provides for its
employees generally, and such other benefits as the Company provides generally for its senior executives. Such fringe benefits may include
paid time off (vacation and sick days), right to unpaid FMLA time off, medical insurance coverage (health, dental and vision), and Employee
Retirement Plan, as may exist from time to time. In addition, the Company shall maintain a Term Life Insurance policy for the Employee,
valued at $2 Million, of which $1 Million shall be assigned to the Company and remaining to the Employee’s Estate.

 

	 	B.	Grant of Series A Preferred Shares

 

As an incentive towards the
ultimate success of the Company, and to provide leadership authority to the Executive, the Company grants 10,204 shares of the Company’s
Series A Preferred Shares to Employee (the “Preferred Stock”) upon execution of this Agreement (the “Grant Date”)
and the Employee accepts such grant for itself and its successors and assigns, as follows:

 

	 	i.	Shareholder Rights Pertaining to Granted Series A Preferred Shares

 

From and after the Grant Date,
Employee will be recorded as a shareholder of the Company with respect to the full amount of the Granted Series A Preferred Shares
less any Shares that are forfeited, transferred back to the Company or otherwise cancelled. Employee shall be entitled, from and after
the Grant Date, to vote the full amount of Granted Shares, whether vested or unvested, less any shares that are forfeited, transferred
back to the Company or otherwise cancelled.

 

	 	ii.	Transfer Restrictions; Vesting

 

(a)Provided that
the Employee has not experienced a Termination of Service and remains continuously employed with the Company, the Employee’s rights
in and to the Shares shall be fully vested on June 30, 2022, and shall be deemed partially vested at 25% for each quarter in quarterly
installments following the Grant Date. Employee’s rights in and to the Shares shall be forfeitable unless and until otherwise vested
pursuant to the terms of this Extension.

 

Shares that have vested and
are no longer subject to forfeiture according to the above vesting schedule are referred to herein as “Vested Shares.”
Shares that have not vested and remain subject to forfeiture under the preceding schedule are referred to herein as “Unvested
Shares.”

 

(b)The vesting period
and the amount of the Award set forth above shall be adjusted on a prorated basis by the Board of Directors to reflect the decreased level
of employment during any period in which the Employee is on an approved leave of absence or is employed on a less than full time basis.

 

(c)Any sale, transfer,
assignment, encumbrance, pledge, hypothecation, conveyance in trust, gift, transfer by bequest, devise or descent, or other transfer or
disposition of any kind, whether voluntary or by operation of law, directly or indirectly, of Unvested Shares shall be strictly prohibited
and void; provided, however, that the Board of Directors, in its sole discretion, may permit the Employee to assign or transfer an Award,
provided that the Award shall be subject to all the terms and condition of this Agreement and any other terms required by the Board of
Directors as a condition to such transfer.

 

	 	iii.	Forfeiture upon Termination of Employment; Company Transaction

 

Upon a Termination of Service
for any reason, including without limitation, termination by the Company for Cause, voluntary resignation by the Employee or the Employee’s
death, Disability or Retirement, the Unvested Shares shall be forfeited by the Employee and cancelled and surrendered to the Company without
payment of any consideration to the Employee.

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date and year first written upon.

 

	For NanoViricides, Inc.	For Employee:
	 	 
	By	/s/ Brian Zucker	 	/s/ Anil Diwan
	 	Name: Brian Zucker	 	ANIL DIWAN
	 	Title: DirectorEX-10.1

 Exhibit 10.1 
  

			
	 Cloud Contact Center
 Software
	  	

 October 10, 2022 

Mr. Michael Burkland 
 Dear Mike, 

We are very pleased to offer you employment with Five9, Inc. (“Company” or “Five9”) for the position of Chief Executive Officer
(“CEO”). You shall have the usual duties of a CEO, including, without limitation, managing the day-to-day business of the Company, developing the
Company’s strategic direction, business plans, and financing and capitalization opportunities, supervising the Company’s executives, communicating with the Company’s Board of Directors (“Board”) and the Company’s
stockholders, and evaluating, negotiating, and executing significant business transactions on behalf of the Company, as well as such other duties as may be assigned to you from time to time by the Board. You shall report to the Board. You will also
continue to serve as Chairman of the Board, until otherwise determined by the Board. 
 You shall agree to serve and be nominated as a member of the Board
during your employment with the Company, and you may be asked to serve as a director of one or more subsidiaries or affiliates of the Company. Upon the severance of your employment for any reason, you shall be deemed to have resigned from the Board
and from all other positions as an officer or director of any of the Company’s subsidiaries or affiliates, provided that beginning on the date that you cease to serve on the Board for any reason (unless you are terminated or resign under
circumstances that would constitute “Cause” as such term is defined in the Company’s 2014 Equity Incentive Plan, or any successor plan) and ending on the earlier to occur of (i) a Change in Control of the Company (as defined in
the Company’s 2014 Equity Incentive Plan, or any successor plan) (“Change in Control”), or (ii) your death, you shall carry the title of “Chairman Emeritus” of the Company, which shall be a non-fiduciary role and shall carry with it no rights (including any right to attend meetings of the Board), authority, duties or responsibilities, and for which you shall receive no compensation. 

Five9, Inc. 
 4000 Executive Parkway, Suite 400 

San Ramon, CA 94583 
 www.five9.com 

 You agree that during your employment with the Company, you will (i) devote as much time and effort as
reasonably necessary for the performance of your responsibilities under this letter, (ii) refrain from engaging in services of any kind (whether as an employee, independent contractor, owner, director, partner, advisor or in any other capacity)
on behalf of a business that, as determined by the Board in its reasonable discretion, competes with the Company (or any of its subsidiaries or affiliates), and (iii) refrain from providing services of any kind or engage in any other business
activity that would materially interfere with the performance of your duties as CEO. As a general policy, you may not serve on more than two public company boards of directors (including the Company’s board of directors), unless such service is
approved by a majority of non-affected members of the Company’s board of directors. In addition, your service on the board of directors (or similar body) of any other business entity, or the provision of
other services to other business entities, is subject to the prior approval of the Board, which shall not be unreasonably withheld. You are permitted to continue your current level of activity with each of the entities listed on Exhibit A.
The Company shall have the right to require you to resign from any board or similar body on which you may then serve if the Board reasonably determines that your service on such board or body interferes with the effective discharge of your duties
and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its affiliates, successors or assigns. You will also follow the Company’s policies and procedures
(including its policies protecting other employees against discrimination and sexual harassment) as described to you from time to time. 
 Your expected
employment start date is November 28, 2022. In this position, you will receive an annual base salary of $585,000, less applicable withholdings, paid according to the Company’s standard payroll practices. In addition, you will be eligible
to earn an annual bonus with a target amount of 100% of base salary, less applicable withholdings, subject to the terms of the Company’s 2022 Executive Bonus Program, and any bonus programs approved by the Compensation Committee for subsequent
periods (“Bonus Program”) and based on the objectives set forth in the Bonus Program. Your bonus will be determined based solely on the Company’s performance against the objectives set forth in the Bonus Program. If earned, your bonus
will be paid on a semi-annual basis, or such other basis as is approved by the Compensation Committee and any bonus paid for the remainder of 2022 will be pro-rated based on your start date. The Compensation
Committee retains sole discretion to determine both eligibility, timing and the amount of any bonus you are eligible to receive. 
 The Company will grant
you (i) an award of restricted stock units (“RSUs”) covering a number of shares of Company common stock with a target dollar value of $14 million and (ii) an award of performance-based restricted stock units
(“PRSUs”) covering a number of shares of Company common stock with a target value of $14 million, in each case as determined under the Company’s Equity Award Grant Policy in effect on the date of this letter. Assuming your
employment start 

  
 2 

 
date is November 28, 2022, in accordance with the Company’s Equity Award Grant Policy, the RSUs and PRSUs would have a grant date of December 12, 2022. The RSUs would have a
vesting commencement date of December 3, 2022 (pursuant to the Company’s standard vesting terms) and would vest as to 1/12 of the total number of shares subject to the RSUs on each March 3, June 3, September 3 and
December 3 thereafter, so that the RSUs are fully vested on December 3, 2025, subject to your continued service on each vesting date. Between 0 and 200% (determined in accordance with the following sentence) of the target number of PRSUs
will be eligible to vest based on the Company’s relative total shareholder return (“RTSR”) performance as compared to the companies in the S&P Software and Services Select Index during three
one-year performance periods consisting of the Company’s 2023, 2024 and 2025 fiscal years. If the Company’s TSR Percentile Rank (as such term is defined in the standard form of PRSU Agreement) is
(i) lower than the 25th percentile, 0% of the PRSUs for such performance period will be eligible to vest, (ii) in the 25th
percentile, then 50% of the target number of PRSUs for such performance period will be eligible to vest, (iii) in the 55th percentile, 100% of the target number of PRSUs for such performance
period will be eligible to vest, or (iv) in the 75th percentile or higher, 200% of the target number of PRSUs for such performance period will be eligible to vest, with the number of shares
eligible to vest interpolated linearly between the levels described in clauses (ii) through (iv) above. 1/3rd of the maximum number of PRSUs may be earned and settled in shares following the end of each
one-year performance period based on RTSR performance and subject to your continued employment through the payment date, but the amount initially paid in 2024 and 2025 (for 2023 and 2024 performance periods)
will be limited to 100% of the target amount of PRSUs for each year, and any portion of the PRSUs resulting from above-target performance in 2023 and 2024 will be paid in 2026, subject to your continued employment through the payment date. If the
Company’s absolute total shareholder return for any performance period is negative, then no more than 100% of the target amount of PRSUs for such period may be earned. If your employment with the Company terminates before the payment date in
2026 due to death or disability, 100% (if due to death) or 50% (if due to disability) of the unvested PRSUs (related to any uncompleted period and above target performance in a completed period) may be earned subject to ultimate RTSR performance in
each remaining performance period. Upon a Change in Control Termination (as such term is defined under the Company’s Key Employee Severance Benefit Plan (“KESP”)), the unvested PRSUs will vest on a double-trigger basis (i) at the
target level for the uncompleted portions of the performance periods and (ii) at the actual level of performance measured through the date of the Change in Control based on the per share price paid to common stockholders in such Change in
Control. The RSUs and PRSUs will each otherwise be governed by the Company’s 2014 Equity Incentive Plan and standard form of RSU and PRSU award agreement. 

You acknowledge and agree that you will not be eligible to receive any further equity incentive awards under the Company’s 2014 Equity Incentive Plan
from the Company during the Company’s annual “refresh grant” cycle for other executives and employees in the first quarter of the 2023 fiscal year. After such annual “refresh grant” cycle, you will be eligible to receive
additional equity incentive awards, from time to time, in the sole discretion of the Compensation Committee of the Board. 

  
 3 

 You will be eligible for benefits provided under the KESP as a Tier 1 Participant. If, at any time during
your employment as Chief Executive Officer, (i) the KESP expires or is terminated and is not replaced with a new plan, contract or arrangement providing total severance benefits that are at least as favorable in the aggregate to you, or
(ii) if your severance benefits under the KESP are reduced, you will continue to be eligible to receive the severance benefits set forth in the KESP for a Tier 1 Participant in effect as of the date of this letter. Capitalized terms set forth
in this paragraph have the meaning set forth in the KESP. 
 As a full-time employee of the Company, you will be eligible to participate in
Company-sponsored vacation policies and employee benefits and be a member of any employee benefit plans that the Company may establish and that are generally available to other executives of the Company. 

Continued Health Plan Coverage 
 Subject to the other
provisions of this letter, you shall be eligible to be covered under the major medical, dental and vision benefit programs that are currently or in the future sponsored by the Company (or an entity in its controlled group), and which are generally
available to active employees (the “Health Plan”), during your tenure as Chief Executive Officer. Subject to the other provisions of this letter, at such time as you cease to serve as the Chief Executive Officer or a director on the Board
(whichever is later), you shall continue to be eligible to be covered under the Health Plan as a former employee of the Company, which, as you know, is a benefit that had been provided under your Chairman Agreement (as defined below) before it was
replaced with this letter. To the extent that you are eligible to be covered under the Health Plan as set forth in this letter, you can elect to cover your spouse and any eligible dependents (each as defined in the Health Plan) under the Health
Plan, all in accordance with the generally applicable provisions of the Health Plan documents regarding coverage of spouses and eligible dependents. 

Subject to the other provisions of this letter, from and after such time as you or a covered spouse or eligible dependent is eligible for Medicare Part A and
Part B (collectively, “Medicare”), the Health Plan will pay secondary to Medicare, in accordance with the generally applicable provisions of the Health Plan documents, and without regard to whether such person is actually enrolled in
Medicare Part A or Part B. 

  
 4 

 The Company shall pay 100% of the cost of the Health Plan premiums for the coverage for you and your covered
spouse and eligible dependents. Notwithstanding the foregoing sentence, if any program under the Health Plan becomes self-funded (in whole or in part), then for the program that is self-funded: (1) you shall pay the Company the cost of such
self-funded coverage, calculated in the same manner as COBRA, for you and your covered spouse’s and eligible dependents’ coverage using your own post-tax resources and (2) such payment will be
due to the Company with respect to each month of coverage within sixty (60) days of the first day of the month of coverage. For example, if the major medical plan first becomes self-funded as of January 1, 2024 and the dental and vision
plans are fully-insured as of that date, you must pay the Company the cost of the January 2024 coverage under the major medical plan by February 29, 2024 and you would not owe any payment to the Company for the premiums related to the vision
and dental plans for January 2024. The Company is required to inform you as soon as reasonably possible in writing if any Health Plan program is self-funded to ensure that you are aware of any obligation to pay the Company for any portion of the
cost of coverage under the Health Plan. 
 Notwithstanding anything in this letter to the contrary, you (and your spouse and eligible dependents) shall only
be entitled to coverage under the Health Plan to the extent that such coverage complies, or using commercially reasonable efforts can be modified to comply (for example, by making the cost of coverage taxable to you), with the nondiscrimination
requirements set forth in Internal Revenue Code (the “Code”) Section 105(h) and Section 2716 of the Public Health Service Act, as incorporated into the Code and the Employee Retirement Income Security Act of 1974, as amended. In
the event that Company in good faith determines that the Health Plan cannot be modified using commercially reasonable efforts (a “Nondiscrimination Event”), the provisions of the paragraph set forth below with the header “EPP”
shall apply. 
 During the time you serve as the Chief Executive Officer and/or as a director on the Board and the Company has Aetna as the insurance
carrier or third-party administrator for the major medical benefit program, you (and your spouse and eligible dependents) shall remain eligible for the major medical benefit program coverage under the Health Plan. 

If you cease to serve as the Chief Executive Officer or a director on the Board or the Company no longer has Aetna as the insurance carrier or third-party
administrator for the major medical benefit program, the Company will use commercially reasonable efforts to continue being able to provide ongoing coverage (“Ongoing Coverage”) for you (and your spouse and eligible dependents) in each of
the programs under the Health Plan. In the event that the Company determines in good faith that in using its commercially reasonable efforts it is unable to obtain commercially reasonable Ongoing Coverage, the Company will provide a runway in order
to allow you a period of time to transition to alternative coverage for the program that is no longer available. The Company shall provide you with at least thirty (30) 

  
 5 

 
days prior written notice before coverage under any of the Health Plan programs is terminated, and this prior written notice requirement applies separately to each program under the Health Plan.
This runway shall begin no later than thirty (30) days prior to the last day of the last plan year in which the Company has determined, in good faith, that it cannot provide Ongoing Coverage for the program to you (such last day, the
“Ongoing Coverage Ending Date”). The runway shall continue for a period ending on the earlier of (A) the 12 month anniversary of the Ongoing Coverage Ending Date and (B) the last date for which the Company is able to negotiate,
using commercially reasonable efforts, continued coverage for you in such program after the Ongoing Coverage Ending Date. For the avoidance of doubt, the obligation described in this paragraph shall apply separately to each of the major medical,
dental, and vision programs. 
 EPP. In the event that you cease to be eligible for Ongoing Coverage in the major medical program under the Health
Plan in accordance with the immediately preceding paragraph or a Nondiscrimination Event has occurred, the Company shall establish a retiree-only employer payment plan under Code Section 106 (“EPP”) that will reimburse you, on a non-taxable basis, for the amount of individual health insurance premiums incurred for coverage for you and your spouse and eligible dependents. The Company shall credit your account under the EPP with $45,000 per
year during your lifetime to be used during such year as described above, with any amounts unused during the year forfeited to the Company. 
 For the
avoidance of doubt, no survivor coverage is available under this letter. The provisions of this letter under the heading “Continued Health Plan Coverage” above shall survive any termination of your employment for any reason, and shall be
conditioned upon you signing and not revoking the Company’s standard form of release as set forth in the KESP (the “KESP Release”). 
 Your
employment with the Company is “at will.” This means that you are free to resign at any time with or without cause or prior notice. Similarly, the Company is free to terminate its employment relationship with you at any time, with or
without cause or prior notice. As you know, Five9 is involved in a highly competitive and quickly evolving industry. Although your job duties, title, compensation and benefits, as well as the Company’s policies and procedures, may change from time-to-time, the “at-will” nature of your employment may only be changed in a document signed by you and the Chairman of the
Board, or if you are the Chairman, by you and the Lead Independent Director of the Board. Your employment with the Company is subject to Five9’s general employment policies, many of which are described in the Five9 Employee Handbook. The
Company shall reimburse you for reasonable legal fees incurred in the negotiation of this Agreement. 

  
 6 

 You hereby agree not to use, disclose to the Company or induce the Company to use any confidential,
proprietary or trade secret information or material belonging to others which comes (or has come) into your knowledge or possession at any time, nor will you use any such information or material in the course of your employment with the Company,
absent authorization from the third-party that owns the information and the Company. You also agree not to ask any applicant, employee or other person to engage in such activities, absent authorization from the third-party that owns the information
and the Company. In the event you believe that your work at the Company would make it difficult for you not to disclose to the Company any confidential, proprietary or trade secret information or materials belonging to others, you will immediately
provide written notice to the Board and the Company’s General Counsel. You further confirm that you have no other agreements, relationships with or commitments to any other person or entity that conflict with your obligations as an employee of
the Company (including but not limited to noncompetition and non-solicitation agreements), and you represent that your employment will not require you to violate any obligation to or confidence with any other
entity or person. 
 For the avoidance of doubt, all of the restrictions, obligations and provisions set forth in the Agreement Regarding Confidential
Information, Intellectual Property Non-Solicitation between you and the Company, dated as of April 16, 2012 (the “Restrictive Covenants Agreement”), shall remain in full force and effect in
accordance with their terms notwithstanding any termination of your employment with, or service on the Board of, the Company (and irrespective of any ambiguous language set forth in the KESP Release). 

Your employment pursuant to this letter is contingent on the following: (1) your ability to provide the Company with the legally-required proof of your
identity and authorization to work in the United States; (2) the Company’s satisfaction that you will not be in violation of any non-compete, proprietary invention and information agreements, or any
other similar agreement between you and any current or former employer or other entity to which you provide or have provided services; and (3) your signing of the Company’s Mutual Arbitration Agreement. 

By execution of this letter, you and the Company hereby terminate the Chairman of the Board Agreement between you and the Company, dated as of June 22,
2020 (the “Chairman Agreement”) and any and all obligations thereunder, effective as of November 28, 2022, which Chairman Agreement is hereby superseded and replaced in its entirety by this letter. For the avoidance of doubt, the
Indemnification Agreement with the Company, dated July 9, 2021(the “Indemnification Agreement”) shall remain in full force and effect in accordance with its terms. 

Mike, we hope that you will accept our employment offer on the above terms and conditions, which can be modified only in writing as signed by the Chairman of
the Board or, if you are the Chairman of the Board, by the Lead Independent Director of the Board. This letter sets forth the terms of your employment with us and supersedes any prior representations or agreements, whether written or oral, excluding
the Restrictive Covenants Agreement, the Indemnification Agreement, and agreements relating to your current equity in the Company, but including any 

  
 7 

 
other agreement between you and the Company (including, without limitation the Chairman Agreement). To accept our offer, please return one copy of your signed letter to me at your earliest
convenience. 
 [Signature page follows] 

  
 8 

 Please contact me if you have any questions whatsoever about this letter or your employment. We are looking
forward to you joining us as the Chief Executive Officer of Five9. 
 Sincerely, 
  

	
	/s/ Dave Welsh
	Dave Welsh
	 Lead Independent Director

 I have read and accept this employment offer: 
  

	
	/s/ Michael Burkland
	Michael Burkland
	
	 October 10, 2022

	 Date

 Exhibit A 

Outside Activities 
 OneStream Software,
LLC 
 ReliaQuest Holdings, LLC or its ultimate parent

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]